Menu
Search
|

Menu

Close
X

Galectin Therapeutics Inc GALT.OQ (NASDAQ Stock Exchange Capital Market)

3.61 USD
+0.07 (+1.98%)
As of Sep 13
Previous Close 3.54
Open 3.54
Volume 35,726
3m Avg Volume 86,438
Today’s High 3.66
Today’s Low 3.54
52 Week High 6.97
52 Week Low 2.95
Shares Outstanding (mil) 45.59
Market Capitalization (mil) 172.80
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-0.202
FY18
-0.385
FY17
-0.498
FY16
-0.733
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
--
7.90
Price to Book (MRQ)
vs sector
37.71
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.64
LT Debt to Equity (MRQ)
vs sector
0.00
12.61
Return on Investment (TTM)
vs sector
-251.11
12.69
Return on Equity (TTM)
vs sector
--
17.13

EXECUTIVE LEADERSHIP

Harold Shlevin
President, Chief Executive Officer, Chief Operating Officer, Since 2018
Salary: $395,833.00
Bonus: $375,000.00
Jack Callicutt
Chief Financial Officer, Secretary, Since 2018
Salary: $275,278.00
Bonus: $213,750.00
Eliezer Zomer
Executive Vice President - Manufacturing and Product Development, Since 2000
Salary: $110,000.00
Bonus: --
Adam Allgood
Executive Director of Clinical Development, Since 2015
Salary: --
Bonus: --
J. Rex Horton
Executive Director - Regulatory Affairs and Quality Assurance, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4960 Peachtree Industrial Blvd S
BERKELEY LAKE   GA   30071-1580

Phone: +1678.6203186

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

SPONSORED STORIES